Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) acted responsibly on behalf of investors’ profitability in the planned $2.1 billion sale to Allergan Inc (NYSE: AGN).

On June 17, 2015, Kythera Biopharmaceuticals Inc (NASDAQ: KYTH)and Allergan Inc (NYSE: AGN) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Allergan will acquire Kythera in a cash and equity transaction valued at $75 per Kythera share.

Based in Westlake Village, CA, and founded in 2004 Kythera Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of prescription products for the aesthetic medicine market internationally. The company was formerly known as AESTHERx, Inc and changed its name to Kythera Biopharmaceuticals Inc in July, 2006.

The investigation is looking to uncover whether Kythera Biopharmaceuticals Inc was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $85.00 per share.

If you purchased Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) prior to June 17, 2015 you should contact Thieler Law Corp at mail@thielerlaw.com  or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185